New pill takes aim at Hard-to-Treat cancers
NCT ID NCT07197554
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side effects. About 171 participants with cancers like Ewing sarcoma, liver cancer, or bile duct cancer will take the drug for 5 days each week.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Hoag Memorial Hospital
RECRUITINGNewport Beach, California, 92263, United States
-
Mass General Brigham Cancer Institute
RECRUITINGBoston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
The City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Can a pill outsmart Tumors' defenses?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a new drug shrink Hard-to-Treat tumors?
- Can engineered immune cells tackle childhood sarcoma?